The OPTIMISTIC clinical evaluation of exercise training and cognitive behavioral therapy paradigms comes to publication.
Feasibility is demonstrated in mammalian models for a therapeutic strategy that increases MBNL by sequestering MBNL-suppressive miRs.
Insights on the mechanisms that underlie muscle atrophy in DM are provided by studies in a new mouse model.
The RNA binding protein, rbFOX1, competes with MBNL in binding to CCUGexp, but not CUGexp repeats, and thereby mitigates DM2.
The review journal, Frontiers in Neurology, is publishing six new articles on myotonic dystrophy.